No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
ATRC241220P22500
- 0.00
- 0.000.00%
15min DelayClose Dec 20 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest22.50Strike Price0.00Turnover0.00%IV26.76%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma6.40Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
No Data
News
Pain Management Devices Global Analysis Report 2024-2034 Featuring Abbott Laboratories, Boston Scientific, Medtronic, Nevro, Baxter, OMRON, Stryker, Teleflex, ICU Medical, AtriCure, and Zynex
AtriCure Coverage Assumed by JP Morgan at Overweight
J.P. Morgan Maintains AtriCure(ATRC.US) With Buy Rating, Maintains Target Price $40
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC) and Mettler-Toledo (MTD)
Cracking The Code: Understanding Analyst Reviews For AtriCure
AtriCure Is Maintained at Buy by Canaccord Genuity